Evidence map›Paper›PMID 42221082›Full record

ArticleFrontiers in medicine2026

The clinical utility of combining D-dimer with the C-reactive protein/albumin ratio for assessing treatment response in pediatric infectious mononucleosis.

Long Ying Zhu, Liang Zhang, Shui Fu, Zuo Jie Li

Abstract read
In one paragraph

Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Long Ying Zhu *Department of Clinical Laboratory, First People's Hospital of Linping District, Hangzhou, Zhejiang Province, China.
Liang Zhang *Department of Clinical Laboratory, First People's Hospital of Linping District, Hangzhou, Zhejiang Province, China.
Shui FuDepartment of Clinical Laboratory, First People's Hospital of Linping District, Hangzhou, Zhejiang Province, China.
Zuo Jie LiDepartment of Clinical Laboratory, The People's Hospital of Cangnan Zhejiang, Wenzhou, Zhejiang Province, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: This study evaluates the effectiveness of tracking D-dimer levels and the CRP/ALB ratio for objective quantification of therapeutic response and complication risk in children with infectious mononucleosis (IM). Methods: This study involved 171 hospitalized children diagnosed with IM, comprising 116 patients without complications and 55 with complications. Measurements of D-dimer, CRP, albumin, and atypical lymphocytes percentage (ALC) were taken within 24 h of admission and again on the fifth day of treatment to calculate the rate of change. Independent predictors were identified through logistic regression analysis, and the model's performance was validated using receiver operating characteristic (ROC) curves in both training and validation cohorts. Results: Although baseline markers were comparable between groups, post-treatment analysis revealed that the complications group exhibited persistent hypercoagulability and inflammation, as evidenced by elevated levels of D-dimer and CRP/ALB, along with a slower decline in atypical lymphocytes percentage (ALC) ( Conclusions: Short-term changes of routine markers, particularly D-dimer and CRP/ALB, in conjunction with fever duration, may facilitate the objective evaluation of therapeutic efficacy and assist in risk stratification for complications in pediatric IM.

Indexed as

atypical lymphocytes percentage (ALC)C-reactive protein-to-albumin ratioD-dimerinfectious mononucleosisrisk stratificationshort-term changes

Identifiers

PMID42221082
PMCPMC13219324

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.